High response rate after intratumoral treatment with interleukin-2-Reference-Cited by-同舟云学术

High response rate after intratumoral treatment with interleukin-2

Published:2010-06-08 Issue:17 Volume:116 Page:4139-4146
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Weide Benjamin,Derhovanessian Evelyna,Pflugfelder Annette,Eigentler Thomas K.,Radny Peter,Zelba Henning,Pföhler Claudia,Pawelec Graham,Garbe Claus

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference20 articles.

1. Management of cutaneous melanoma;Tsao;N Engl J Med.,2004

2. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?;Eggermont;Eur J Cancer.,2004

3. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases;Grunhagen;Ann Surg.,2004

4. The role of surgery in treatment of stage IV melanoma;Young;J Surg Oncol.,2006

5. In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2;Lotze;J Immunol.,1985

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth;Advanced Healthcare Materials;2024-07-15

2. Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions;Radiology;2024-07-01

3. Kutane Metastasen: Von der Epidemiologie bis zur Therapie;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-07

4. Cutaneous metastases: From epidemiology to therapy;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-06-18

5. Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy;Bioconjugate Chemistry;2024-06-17